Study shows increased IPL sessions increased response rate of treatment in moderate-to-severe MGD

News
Article

The study authors also noted that patients responding well to routine intense pulsed light sessions do not need to undergo additional sessions.

Closeup of eyelid inflammation Image Credit: AdobeStock/OHishi_Foto

Image Credit: AdobeStock/OHishi_Foto

A new study reports that increasing the number of intense pulsed light (IPL) sessions is beneficial for patients with moderate-to-severe meibomian gland dysfunction (MGD) to increase the response rate of treatment.1 The study was conducted by Yang Lu, MD, first author, and colleagues from the Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, and the NHC Key Laboratory of Myopia, Fudan University, both in Shanghai, China.

The clinicians conducted this retrospective study to determine if 90 Asian adult patients with moderate–to–severe MGD could benefit from increasing the number of IPL treatment sessions. Moderate-to-severe MGD is classified as stages 3 to 4.

The patients were divided into 2 groups: 30 patients in group 1 underwent 5 sessions of IPL and 63.3% of them also had expression of the meibomian glands, and 60 patients in group 2 underwent 3 sessions of IPL and 60% also underwent meibomian gland expression.

Results of group comparison

The investigators found that in both groups the symptoms and most clinical indices improved after the IPL treatment sessions finished.

They did not observe a statistical difference in any of the improvement levels of all symptomatic and physical indices, including the ocular surface disease index, tear film break–up time, Demodex, corneal staining, meibum quality, meibomian gland expressibility, and MGD stage (p ≥ 0.05 for all comparisons) between the 2 groups at any time, that is month by month and at the final visit.

However, the investigators did see that the response rate in group 1 after the 5 session of IPL increased compared to the patients in group 2 who were treated with 3 session of IPL treatment (70.0% vs. 63.33%, respectively).

The authors commented, “Increasing the number of IPL sessions is beneficial for patients with moderate-to-severe MGD to increase the response rate of treatment rather than the improvement level. However, there is no need for patients who respond well to a routine number of IPL treatments to undergo additional IPL sessions.”

Reference:
  1. Lu Y, Gong L, Yin Y. Need to increase the number of intense pulsed light (IPL) treatment sessions for patients with moderate to severe meibomian gland dysfunction (MGD). Curr Eye Res. 2024;49:362–367; https://doi.org/10.1080/02713683.2023.2297344
Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
© 2025 MJH Life Sciences

All rights reserved.